Cyclerion Therapeutics (NASDAQ:CYCN) released its earnings results on Monday. The company reported ($1.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.34), Bloomberg Earnings reports. The company had revenue of $1.63 million during the quarter.

NASDAQ:CYCN opened at $8.56 on Wednesday. The business’s 50-day moving average price is $10.83. Cyclerion Therapeutics has a 52-week low of $8.14 and a 52-week high of $21.00.

Separately, Credit Suisse Group assumed coverage on Cyclerion Therapeutics in a report on Monday, June 3rd. They set a “neutral” rating on the stock.

Cyclerion Therapeutics Company Profile

There is no company description available for Cyclerion Therapeutics Inc

Read More: What are the benefits of momentum investing?

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with's FREE daily email newsletter.